Latest Conference Articles

March 11th 2016, 3:33pm

PER® Miami Breast Cancer Conference

Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses a clinical trial examining nelipepimut-S plus GM-CSF vaccine therapy as a treatment for patients with breast cancer.

March 11th 2016, 3:06pm

PER® Miami Breast Cancer Conference

The rapid advance of oncology drug development requires evolving beyond using overall survival in randomized trials as the only acceptable endpoint.

March 11th 2016, 2:27pm

PER® Miami Breast Cancer Conference

There is no clearly acceptable answer to the question of what is the appropriate margin for ductal carcinoma in situ.

March 11th 2016, 8:31am

PER® Miami Breast Cancer Conference

Carboplatin shows promise in treating metastatic BRCA-mutated triple negative breast cancer.

March 11th 2016, 6:46am

PER® Miami Breast Cancer Conference

William F. Symmans, MB, ChB, Division of Pathology/Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, discusses the institution's Moon Shots program for patients with triple-negative breast cancer.

March 10th 2016, 3:53pm

PER® Miami Breast Cancer Conference

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses using the word "cure" in patients with breast cancer who have not had recurrences of disease.

March 9th 2016, 8:59am

Multidisciplinary Head and Neck Cancer Symposium

Jonathan D. Schoenfeld, MD, MPH, physician, assistant professor of Radiation Oncology, Harvard Medical School, Dana Farber Cancer Center on the immunologic effects of chemotherapy and radiation in head and neck cancer.

March 9th 2016, 7:36am

Multidisciplinary Head and Neck Cancer Symposium

Ezra Cohen, MD, Associate Director, Professor of Medicine Moores Cancer Center, UC San Diego, discusses if lenvatinib should be used in the frontline or second-line setting in differentiated thyroid cancer.

March 8th 2016, 3:28pm

Multidisciplinary Head and Neck Cancer Symposium

David Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.

March 4th 2016, 7:11am

Community Oncology Conference

The 2016 Community Oncology Conference, Innovation in Cancer Care: Moving From Theory to Practice, from April 13-15, will feature an expanded lineup of clinical presentations.

March 1st 2016, 2:34pm

Multidisciplinary Head and Neck Cancer Symposium

Randal S. Weber, MD, FACS, professor, department chair, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses future treatment approaches for patients with melanoma.

February 26th 2016, 12:45pm

Multidisciplinary Head and Neck Cancer Symposium

Jessica Frakes, MD, assistant professor of Radiation Oncology, Department of Radiation Oncology, Moffitt Cancer Center, discusses management of toxicities associated with treatment of patients with HPV-positive oropharyngeal squamous cell carcinoma.

February 25th 2016, 3:23pm

Multidisciplinary Head and Neck Cancer Symposium

Renato G. Martins, MD, medical director of Outpatient General Oncology/Hematology at Seattle Cancer Care Alliance, medical director of Thoracic/Head and Neck Oncology, and professor at the University of Washington School of Medicine, discusses side effects that are associated with lenvatinib (Lenvima).

February 23rd 2016, 12:44pm

Multidisciplinary Head and Neck Cancer Symposium

An early-stage trial is examining the addition of nivolumab to a cetuximab regimen in head and neck squamous cell carcinoma.

February 23rd 2016, 6:56am

Multidisciplinary Head and Neck Cancer Symposium

The combination of pazopanib (Votrient) and cetuximab (Erbitux) showed a disease control rate of 77% in patients with recurrent or metastatic head and neck squamous cell carcinoma, including patients with cetuximab- or platinum-resistant disease.

February 22nd 2016, 12:42pm

Multidisciplinary Head and Neck Cancer Symposium

Among patients with HPV-negative, locoregionally advanced head and neck squamous cell carcinoma with a poor prognosis, adding cetuximab (Erbitux) to induction chemotherapy and hyperfractionated or accelerated chemoradiation therapy produced long-term control.

February 22nd 2016, 8:27am

Multidisciplinary Head and Neck Cancer Symposium

James Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses an analysis of a phase II study examining the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.

February 22nd 2016, 7:08am

Multidisciplinary Head and Neck Cancer Symposium

Renato G. Martins, MD, discusses the impact of lenvatinib in patients with differentiated thyroid cancer, how and when it should be used in clinical practice, and the future potential for the agent.

February 20th 2016, 3:19pm

Multidisciplinary Head and Neck Cancer Symposium

Maria E. Cabinillas, MD, associate professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses administering lenvatinib (Lenvima) as a first-line therapy for patients with differentiated thyroid cancer (DTC).

February 20th 2016, 12:38pm

Multidisciplinary Head and Neck Cancer Symposium

Both progression-free and overall survival with second-line afatinib (Gilotrif) in recurrent or metastatic head and neck squamous cell carcinoma are associated with several biomarkers.